A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
NCT01262235
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
68
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Neuroendocrine Tumors
NET
Adrenocortical Carcinoma
ACC
Interventions
DRUG:
TKM-080301
Sponsor
Arbutus Biopharma Corporation